![conference banner](/images/conference-banner.jpeg)
Abstract
Results from clinical studies have demonstrated that inhibitors of histone deacetylase (HDAC) enzymes possess promise for the treatment of several types of cancer. Zolinza® (widely known as SAHA) has been approved by the FDA for the treatment of T-cell lymphoma. As a continuity of our ongoing research to find novel small molecules to target these important enzymes, we synthesized a series of benzothiazole-containing analogues of SAHA and found several compounds with very potent anticancer cytotoxicity. In this study, three more compounds of this type, including N1-(6- chlorobenzo[d]thiazol-2-yl)-N8-hydroxyoctanediamide (3a), N1-[6-(trifluoromethyl)benzo[d]thiazol-2-yl]-N8-hydroxyoctanediamide (3b) and N1-(thiazol-2-yl)-N8-hydroxyoctanediamide (6) were synthesized and evaluated for HDAC inhibition and cytotoxic activities. All three compounds showed very potent HDAC inhibitory effects. Docking revealed that both two compounds 3a, 3b showed higher affinities towards HDAC8 compared to SAHA. In vitro, compound 3a exhibited cytotoxicity equipotent to SAHA against five human cancer cell lines. In term of in vivo activity, compound 3a demonstrated equivalent efficacy to SAHA in mouse xenograft model.
Keywords: Histone deacetylase inhibitors, benzothiazole, heterocycle.
Medicinal Chemistry
Title:New Benzothiazole/thiazole-Containing Hydroxamic Acids as Potent Histone Deacetylase Inhibitors and Antitumor Agents
Volume: 9 Issue: 8
Author(s): Truong Thanh Tung, Dao Thi Kim Oanh, Phan Thi Phuong Dung, Van Thi My Hue, Sang Ho Park, Byung Woo Han, Youngsoo Kim, Jin-Tae Hong, Sang-Bae Han and Nguyen-Hai Nam
Affiliation:
Keywords: Histone deacetylase inhibitors, benzothiazole, heterocycle.
Abstract: Results from clinical studies have demonstrated that inhibitors of histone deacetylase (HDAC) enzymes possess promise for the treatment of several types of cancer. Zolinza® (widely known as SAHA) has been approved by the FDA for the treatment of T-cell lymphoma. As a continuity of our ongoing research to find novel small molecules to target these important enzymes, we synthesized a series of benzothiazole-containing analogues of SAHA and found several compounds with very potent anticancer cytotoxicity. In this study, three more compounds of this type, including N1-(6- chlorobenzo[d]thiazol-2-yl)-N8-hydroxyoctanediamide (3a), N1-[6-(trifluoromethyl)benzo[d]thiazol-2-yl]-N8-hydroxyoctanediamide (3b) and N1-(thiazol-2-yl)-N8-hydroxyoctanediamide (6) were synthesized and evaluated for HDAC inhibition and cytotoxic activities. All three compounds showed very potent HDAC inhibitory effects. Docking revealed that both two compounds 3a, 3b showed higher affinities towards HDAC8 compared to SAHA. In vitro, compound 3a exhibited cytotoxicity equipotent to SAHA against five human cancer cell lines. In term of in vivo activity, compound 3a demonstrated equivalent efficacy to SAHA in mouse xenograft model.
Export Options
About this article
Cite this article as:
Tung Thanh Truong, Kim Oanh Thi Dao, Phuong Dung Thi Phan, My Hue Thi Van, Park Ho Sang, Han Woo Byung, Kim Youngsoo, Hong Jin-Tae, Han Sang-Bae and Nam Nguyen-Hai, New Benzothiazole/thiazole-Containing Hydroxamic Acids as Potent Histone Deacetylase Inhibitors and Antitumor Agents, Medicinal Chemistry 2013; 9 (8) . https://dx.doi.org/10.2174/15734064113099990027
DOI https://dx.doi.org/10.2174/15734064113099990027 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Traditional Herbal Formulation on Experimental Models of Ulcerative Colitis
The Natural Products Journal Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer
Current Drug Targets The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances in Herbal Nanomedicines for Cancer Treatment
Current Molecular Pharmacology Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research High Seroprevalence of Human Herpesvirus 8 Infection in HIV-positive Homosexual Men in Jiangsu Province, China
Current HIV Research Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Unfolded Protein Response in Chronic Obstructive Pulmonary Disease: Smoking, Aging and Disease: A SAD Trifecta
Current Molecular Medicine Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology Correlation between Potassium Channel Expression and Sensitivity to Drug-induced Cell Death in Tumor Cell Lines
Current Pharmaceutical Design Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) A Focused Review on Molecular Signalling Mechanisms of Ginsenosides Anti-Lung Cancer and Anti-inflammatory Activities
Anti-Cancer Agents in Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients
Current Cancer Drug Targets NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation
Current Immunology Reviews (Discontinued)